vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Revolve Group, Inc. (RVLV). Click either name above to swap in a different company.
Revolve Group, Inc. is the larger business by last-quarter revenue ($324.4M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Revolve Group, Inc. runs the higher net margin — 5.7% vs 1.6%, a 4.1% gap on every dollar of revenue. On growth, Revolve Group, Inc. posted the faster year-over-year revenue change (10.4% vs 5.0%). Over the past eight quarters, Revolve Group, Inc.'s revenue compounded faster (9.5% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Revolve Theatre Company is a Henley-on-Thames based theatre company specialising in political and Shakespearean plays. The company is owned by Oliver Dench, Joe Morris and Tom Smith.
PCRX vs RVLV — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $324.4M |
| Net Profit | $2.9M | $18.6M |
| Gross Margin | — | 53.3% |
| Operating Margin | 3.9% | 6.3% |
| Net Margin | 1.6% | 5.7% |
| Revenue YoY | 5.0% | 10.4% |
| Net Profit YoY | — | 50.4% |
| EPS (diluted) | $0.07 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $324.4M | ||
| Q3 25 | $179.5M | $295.6M | ||
| Q2 25 | $181.1M | $309.0M | ||
| Q1 25 | $168.9M | $296.7M | ||
| Q4 24 | $187.3M | $293.7M | ||
| Q3 24 | $168.6M | $283.1M | ||
| Q2 24 | $178.0M | $282.5M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $18.6M | ||
| Q3 25 | $5.4M | $21.2M | ||
| Q2 25 | $-4.8M | $10.2M | ||
| Q1 25 | $4.8M | $11.8M | ||
| Q4 24 | — | $12.3M | ||
| Q3 24 | $-143.5M | $11.0M | ||
| Q2 24 | $18.9M | $15.4M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 53.3% | ||
| Q3 25 | 80.9% | 54.6% | ||
| Q2 25 | 77.4% | 54.1% | ||
| Q1 25 | 79.7% | 52.0% | ||
| Q4 24 | 78.7% | 52.5% | ||
| Q3 24 | 76.9% | 51.2% | ||
| Q2 24 | 75.1% | 54.0% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 6.3% | ||
| Q3 25 | 3.5% | 7.1% | ||
| Q2 25 | 4.7% | 5.8% | ||
| Q1 25 | 1.2% | 5.0% | ||
| Q4 24 | 13.2% | 3.9% | ||
| Q3 24 | -82.8% | 5.0% | ||
| Q2 24 | 15.9% | 5.8% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 5.7% | ||
| Q3 25 | 3.0% | 7.2% | ||
| Q2 25 | -2.7% | 3.3% | ||
| Q1 25 | 2.8% | 4.0% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | -85.1% | 3.9% | ||
| Q2 24 | 10.6% | 5.4% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.27 | ||
| Q3 25 | $0.12 | $0.29 | ||
| Q2 25 | $-0.11 | $0.14 | ||
| Q1 25 | $0.10 | $0.16 | ||
| Q4 24 | $0.38 | $0.18 | ||
| Q3 24 | $-3.11 | $0.15 | ||
| Q2 24 | $0.39 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $292.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $512.5M |
| Total Assets | $1.2B | $765.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $292.3M | ||
| Q3 25 | $246.3M | $315.4M | ||
| Q2 25 | $445.9M | $310.7M | ||
| Q1 25 | $493.6M | $300.8M | ||
| Q4 24 | $484.6M | $256.6M | ||
| Q3 24 | $453.8M | $252.8M | ||
| Q2 24 | $404.2M | $244.7M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $512.5M | ||
| Q3 25 | $727.2M | $490.2M | ||
| Q2 25 | $757.8M | $468.6M | ||
| Q1 25 | $798.5M | $453.4M | ||
| Q4 24 | $778.3M | $437.8M | ||
| Q3 24 | $749.6M | $420.8M | ||
| Q2 24 | $879.3M | $405.8M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $765.0M | ||
| Q3 25 | $1.3B | $751.3M | ||
| Q2 25 | $1.5B | $722.9M | ||
| Q1 25 | $1.6B | $713.9M | ||
| Q4 24 | $1.6B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.6B | $657.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-10.2M |
| Free Cash FlowOCF − Capex | — | $-13.3M |
| FCF MarginFCF / Revenue | — | -4.1% |
| Capex IntensityCapex / Revenue | — | 1.0% |
| Cash ConversionOCF / Net Profit | — | -0.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $48.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-10.2M | ||
| Q3 25 | $60.8M | $11.8M | ||
| Q2 25 | $12.0M | $12.6M | ||
| Q1 25 | $35.5M | $45.1M | ||
| Q4 24 | $33.1M | $3.9M | ||
| Q3 24 | $53.9M | $9.1M | ||
| Q2 24 | $53.2M | $-24.7M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-13.3M | ||
| Q3 25 | $57.0M | $7.5M | ||
| Q2 25 | $9.3M | $10.4M | ||
| Q1 25 | $26.9M | $43.4M | ||
| Q4 24 | $31.0M | $2.1M | ||
| Q3 24 | $49.8M | $8.0M | ||
| Q2 24 | $51.6M | $-25.7M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -4.1% | ||
| Q3 25 | 31.7% | 2.5% | ||
| Q2 25 | 5.1% | 3.4% | ||
| Q1 25 | 15.9% | 14.6% | ||
| Q4 24 | 16.6% | 0.7% | ||
| Q3 24 | 29.6% | 2.8% | ||
| Q2 24 | 29.0% | -9.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 2.2% | 1.5% | ||
| Q2 25 | 1.5% | 0.7% | ||
| Q1 25 | 5.1% | 0.6% | ||
| Q4 24 | 1.1% | 0.6% | ||
| Q3 24 | 2.4% | 0.4% | ||
| Q2 24 | 0.9% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.55× | ||
| Q3 25 | 11.20× | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | 7.37× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | 2.82× | -1.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
